Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

TNF-alpha antagonist therapy modify the tuberculin skin test response (TST)


  • Please log in to reply
No replies to this topic

#1 Jeannie McClelland

Jeannie McClelland

    Senior Gold Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 1,706 posts
  • Location:in the Rocky Mountains of the USA

Posted 11 April 2010 - 03:15 AM

TNF-alpha antagonist therapy modify the tuberculin skin test response (TST). Tumour necrosis factor-alpha (TNF-α) antagonist drugs have been associated with increased risk of tuberculosis (TB). Increased TST responses in patients receiving TNF-α antagonists may be associated with the restoration of suppressed immune reactivity against TB antigens with the decreased disease activity. Tulin Cagatay. (SpringerLink) Rheumatology International. 27 March 2010. (Also see: TNF Inhibitors and Tuberculosis and Scleroderma)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Jeannie McClelland
(Retired) ISN Director of Support Services
(Retired) ISN Sclero Forums Manager
(Retired) ISN Blog Manager
(Retired) ISN Assistant News Guide
(Retired) ISN Artist
International Scleroderma Network